

Market Announcement

13 March 2026

Immutep Limited (ASX: IMM) – Reinstatement to Quotation

Description

The suspension of trading in the securities of Immutep Limited ('IMM') will be lifted immediately following the release by IMM of an announcement regarding the outcome of the pre-specified interim futility analysis for the TACTI-004 (KEYNOTE-F91) Phase III trial evaluating its lead candidate, eftilagimod alfa.

Issued by

ASX Compliance